Corvidia Therapeutics Secures $26,000,000 Series A Funding

  • Feed Type
  • Date
    2/18/2016
  • Company Name
    Corvidia Therapeutics
  • Mailing Address
    35 Gatehouse Drive Waltham, MA 02451 USA
  • Company Description
    Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company’s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations.
  • Website
    http://www.corvidiatx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $26,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Funds from the Series A financing will be used to progress COR-001 into Phase I/II clinical trials during 2016, as well as to advance the company’s preclinical pipeline.
  • M&A Terms
  • Venture Investor
    Apple Tree Partners
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Investor

Trending on Xconomy